The history of pharmacology is fundamentally a history of translation. Every major therapeutic achievement has required the conversion of scientific knowledge into interventions capable of improving human health. From conventional small-molecule drugs to biologics, gene therapies, and precision medicines, pharmacology has continuously evolved with advances in biomedical science. Nevertheless, scientific discovery does not always lead to clinical success. Identification of a molecular target or demonstration of biological activity in experimental systems does not guarantee development of an effective therapy. The pathway from discovery to clinical application remains associated with high failure rates, uncertainty, and substantial investment. Traditional drug development follows a sequential pathway involving target identification, preclinical evaluation, clinical trials, regulatory approval, and post-marketing surveillance. Although this approach has generated major therapeutic advances, increasing understanding of biological complexity has revealed important limitations. Human diseases are rarely caused by isolated molecular abnormalities; instead, they result from interactions among biological pathways, genetic factors, environmental influences, and individual patient characteristics. This complexity is particularly evident in cancer, neurodegenerative disorders, autoimmune diseases, and metabolic conditions. Patients with similar clinical diagnoses may have different molecular profiles and therapeutic responses. Consequently, the concept of developing a single therapy for a broadly defined disease population is increasingly being replaced by strategies aimed at identifying the most appropriate treatment for specific patients. Translational pharmacology represents this evolving paradigm. Translation should no longer be considered a final step after laboratory discovery but rather an integrated process beginning at the earliest stages of therapeutic development and continuing through clinical implementation. The central challenge of modern pharmacology is therefore shifting from discovering molecules capable of modifying biological pathways toward determining whether these interventions can provide meaningful benefit in real-world clinical settings. Several emerging approaches are accelerating this transformation. Biomarkers improve patient selection and treatment monitoring. Pharmacogenomics enhances understanding of variability in drug response. Human-relevant models increase confidence in preclinical prediction. Artificial intelligence enables analysis of complex biological datasets. Model-informed drug development improves decision-making, and real-world evidence expands knowledge beyond controlled clinical trials. However, technology alone cannot overcome the translational challenge. Successful translation requires integration of scientific innovation with clinical expertise, regulatory science, healthcare implementation, and patient perspectives. The future success of pharmacology will depend not only on generating new discoveries but also on creating reliable pathways through which discoveries improve patient outcomes.
Zabihi, M. (2026). Translational Pharmacology: Bridging Scientific Discovery and Patient Care. Advances in Pharmacology and Therapeutics Journal, (), 68–77.
MLA
Zabihi, M. "Translational Pharmacology: Bridging Scientific Discovery and Patient Care", Advances in Pharmacology and Therapeutics Journal, , 2026, 68–77.
HARVARD
Zabihi, M. (2026). 'Translational Pharmacology: Bridging Scientific Discovery and Patient Care', Advances in Pharmacology and Therapeutics Journal, (), pp. 68–77.
CHICAGO
Zabihi, M., "Translational Pharmacology: Bridging Scientific Discovery and Patient Care." Advances in Pharmacology and Therapeutics Journal, (2026): 68–77,
VANCOUVER
Zabihi M. Translational Pharmacology: Bridging Scientific Discovery and Patient Care. Adv Pharmacol Ther J. 2026;():68–77.
